TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Ultrasound elastography is an advanced imaging technique that assesses tissue stiffness or elasticity by using ultrasound waves. Unlike conventional ultrasound, which primarily visualises anatomy, elastography quantifies how tissues deform under compression or shear, providing crucial diagnostic clues for tumours, fibrosis and other pathologies.
Two principal modalities dominate the market: strain elastography, which measures tissue strain under manual compression, and shear‑wave elastography, which evaluates the propagation speed of shear waves generated by acoustic radiation force. Their non‑invasive nature and real‑time feedback have driven rapid adoption across oncology, cardiology, musculoskeletal and liver disease assessment.
Continued growth is underpinned by rising prevalence of chronic liver disease, expanding cancer screening programmes, and the shift toward portable point‑of‑care solutions that enable bedside elasticity assessment.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast perio
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
The global Sono-elastography market was valued at USD 2.8 billion in 2025 and is projected to reach US$ 5.6 billion by 2034, at a CAGR of 7.0% during the forecast period.
Ultrasound elastography is an advanced imaging technique that assesses tissue stiffness or elasticity by utilizing ultrasound waves. Unlike conventional ultrasound, which primarily visualizes anatomical structures, elastography quantifies how tissues deform under compression or vibration, providing critical diagnostic information. Two principal modalities are used: strain elastography, evaluating tissue strain under manual compression, and shear‑wave elastography, measuring the propagation speed of shear waves to calculate elasticity. This non‑invasive approach has become indispensable in oncology, cardiology, and musculoskeletal imaging, enhancing diagnostic accuracy and guiding therapeutic decisions.
The United States market is estimated at approximately USD 0.78 billion in 2025, while China is projected to reach around USD 0.70 billion, reflecting strong adoption driven by expanding healthcare infrastructure and increasing prevalence of chronic diseases.
The portable Sono‑elastography segment is expected to attain USD 1.2 billion by 2034, growing at a robust 9% CAGR over the next six years, propelled by demand for point‑of‑care diagnostics in ambulatory and remote settings.
Key global players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International Limited, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp, and SuperSonic Imagine. Collectively, the top five manufacturers accounted for roughly 45% of total market revenue in 2025.
Shear‑Wave Elastography Segment Dominates the Market Due to Superior Quantitative Accuracy and Real‑Time Capability
The market is segmented based on type into:
Strain elastography
Shear‑wave elastography
2‑D shear‑wave imaging
3‑D shear‑wave imaging
Mini‑probe devices
Portable units
Others
Oncology Segment Leads Due to High Demand for Non‑Invasive Tumor Staging and Treatment Monitoring
The market is segmented based on application into:
Oncology
Cardiology
Gynecology & Obstetrics
Musculoskeletal & Orthopedic
Vascular Diagnosis
Neurology
Others
Hospitals Segment Drives Growth Owing to Large‑Scale Imaging Departments and Advanced Diagnostic Needs
The market is segmented based on end‑user into:
Hospitals
Diagnostic Imaging Centers
Research & Academic Institutions
Physician Offices
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the Sono‑elastography market is semi‑consolidated, with large multinational manufacturers, regional specialists, and emerging innovators. Samsung Medison leads the market, leveraging its extensive ultrasound platform and integrated elastography solutions that are deployed across North America, Europe, and Asia‑Pacific.
GE Healthcare and Philips Healthcare also command substantial shares in 2024, driven by their advanced shear‑wave technologies and strong service networks that support high‑throughput clinical environments.
Furthermore, these companies’ growth initiatives—such as geographic expansion into emerging markets, strategic acquisitions of niche elastography firms, and the launch of portable‑handheld systems—are expected to expand market share significantly over the forecast period.
Meanwhile, Siemens Healthineers and Hitachi Ltd. are reinforcing their position through sizable R&D investments, collaborations with academic institutions, and the introduction of AI‑enhanced image analysis tools, ensuring sustained competitiveness in the evolving landscape.
Samsung Medison
GE Healthcare
Philips Healthcare
Siemens Healthineers
Hitachi Ltd.
Mindray Medical International Limited
Fujifilm Holdings Corporation
Canon Medical Systems Corporation
Landwind Medical
Esaote S.p.A.
SonoScape Medical Corp
SuperSonic Imagine
In recent years, ultrasound elastography has transitioned from a niche research tool to a mainstream clinical asset, driven by rapid advances in imaging hardware, signal‑processing algorithms, and artificial‑intelligence (AI)‑enhanced quantification. The global Sono‑elastography market was valued at US$1.5 billion in 2025 and is projected to reach US$3.2 billion by 2034, registering a compounded annual growth rate of 7.2 % over the forecast period. This growth is underpinned by the technology’s ability to non‑invasively assess tissue stiffness—a surrogate marker for fibrosis, tumor infiltration, and plaque stability—thereby augmenting diagnostic confidence in oncology, cardiology, and musculoskeletal medicine. Two principal modalities dominate the market: strain elastography, which gauges tissue deformation under manual or acoustic compression, and shear‑wave elastography, which derives absolute elasticity values from the propagation speed of shear waves generated by focused acoustic push pulses. The latter, owing to its quantitative output and reproducibility, has been quickly adopted in liver fibrosis staging, breast lesion characterization, and arterial plaque assessment. Moreover, integration of AI‑based pattern‑recognition tools enables automated region‑of‑interest selection and reduces operator dependency, accelerating workflow in busy imaging departments. As reimbursement frameworks across North America, Europe, and Asia increasingly recognize the clinical value of elastography‑derived metrics, hospitals are investing in hybrid systems that combine conventional B‑mode imaging with dedicated elastography packages, further expanding the install base. Parallel to hardware upgrades, manufacturers have introduced portable, battery‑operated units that deliver shear‑wave capabilities at the point‑of‑care, a development that is reshaping diagnostic pathways in community clinics and emergent settings.
Personalized Diagnostics
The push toward personalized diagnostics is reshaping the demand landscape for Sono‑elastography. Clinicians now seek imaging biomarkers that can stratify patients for targeted therapies, monitor treatment response, and predict disease progression. In oncology, elastography‑derived stiffness maps are being correlated with molecular subtypes of breast and prostate cancers, enabling oncologists to tailor neoadjuvant strategies. In cardiology, shear‑wave measurements of myocardial tissue elasticity are emerging as early indicators of myocardial fibrosis, influencing decisions on anti‑remodeling drugs. The United States market is estimated at US$500 million in 2025, while China is projected to reach US$400 million, reflecting robust adoption in regions with high incidence of chronic liver disease and cancer screening programs. Portable sonography platforms, now capable of delivering high‑resolution shear‑wave data, are expected to achieve a market size of US$250 million by 2034, growing at an estimated 9 % CAGR over the next six years. This surge is fueled by the need for bedside assessment in intensive‑care units, remote clinics, and intra‑operative settings, where rapid, quantitative tissue characterization informs real‑time decision making. Furthermore, the amalgamation of elastography data with genomic and proteomic profiles—often housed within hospital information systems—facilitates a multidimensional view of disease, supporting clinicians in delivering truly individualized care pathways.
Clinical adoption of Sono‑elastography is expanding across a spectrum of specialties, driven by compelling evidence of its diagnostic utility and cost‑effectiveness. In liver disease management, shear‑wave elastography has become a first‑line non‑invasive alternative to biopsy, reducing procedural complications and health‑care expenditures. Orthopedic surgeons increasingly rely on elastography to differentiate between soft‑tissue tumors and benign cysts, while vascular specialists employ it to assess plaque composition, guiding interventional strategies. The competitive landscape reflects this momentum: the global top five manufacturers—Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, and Hitachi Ltd.—collectively accounted for approximately 45 % of total market revenue in 2025. These incumbents are intensifying R&D pipelines, launching next‑generation transducers with higher frequency ranges, and forging partnerships with AI start‑ups to enhance image analysis. Emerging challengers such as Mindray, Fujifilm, and Esaote are targeting price‑sensitive markets by offering compact, cost‑effective solutions without compromising shear‑wave performance. Nevertheless, the market faces obstacles, including variability in measurement standards across vendors, the need for extensive operator training, and regulatory scrutiny surrounding AI‑driven diagnostic claims. To mitigate these challenges, industry consortia are working toward harmonized accreditation protocols and robust clinical validation studies. As reimbursement policies evolve to cover elastography‑based examinations and as insurers recognize the long‑term savings from early disease detection, the trajectory of market growth is expected to remain upward, cementing Sono‑elastography as an indispensable component of modern diagnostic imaging.
North America currently commands the largest share of the global Sono‑elastography market. The United States leads the region thanks to a mature healthcare infrastructure, strong reimbursement policies for advanced imaging, and a high concentration of research hospitals that adopt shear‑wave and strain elastography for liver fibrosis, breast cancer, and musculoskeletal assessments. The Federal‑Aided funding for AI‑enabled diagnostics accelerates integration of quantitative elastography metrics into routine scans, encouraging manufacturers to launch next‑generation platforms in the region. Canada follows closely, driven by its publicly funded health system that emphasizes cost‑effectiveness; Canadian clinics are increasingly purchasing portable elastography units to serve remote and Indigenous communities, expanding the addressable market. Mexico, while smaller, is witnessing growing private‑sector investment in tertiary care centers that purchase on‑platform elastography modules to compete with U.S. providers for cross‑border patients. Overall, the combination of robust clinical evidence, payer support, and a pipeline of innovative devices sustains North America’s dominant position.
Key Highlights:
Asia‑Pacific is projected to post the fastest compound annual growth rate over the forecast horizon. China’s accelerating adoption of non‑invasive cancer screening aligns with national guidelines that recommend elastography for early detection of hepatic and breast lesions, creating a vast patient pool. Japanese hospitals, known for early adoption of high‑resolution imaging, are expanding shear‑wave capabilities to cardiac and thyroid applications, spurred by an ageing population that demands precise tissue characterization. India’s private‑sector hospitals are rapidly upgrading to portable elastography units to differentiate between malignant and benign masses, driven by rising out‑of‑pocket spending and growing awareness of early‑diagnosis benefits. South Korea and Southeast Asian economies (e.g., Singapore, Thailand) are investing heavily in digital health initiatives, integrating elastography data into tele‑radiology platforms that serve rural clinics. Government‑backed healthcare modernization programs across the region prioritize equipment that reduces biopsy rates, positioning Sono‑elastography as a cost‑saving, patient‑centric technology.
Key Highlights:
The convergence of artificial‑intelligence algorithms with elastography measurements is reshaping demand patterns worldwide. In North America, FDA‑cleared AI modules that automatically calculate shear‑wave velocity and flag suspicious patterns have shortened exam times, prompting radiology departments to increase exam volumes. European regulators, particularly the EU Medical Device Regulation, require validated quantitative metrics; this has accelerated the uptake of AI‑enhanced elastography in German and French academic centers where standardised reporting is mandatory. In Asia‑Pacific, AI‑driven cloud platforms enable real‑time sharing of elastography images for multidisciplinary tumor boards, expanding the clinical utility beyond the point‑of‑care and encouraging hospitals to invest in higher‑end consoles. The alignment of clinical guidelines—such as the American Association for the Study of Liver Diseases (AASLD) and the Asian Pacific Association for the Study of the Liver (APASL)—with quantitative elastography thresholds further cements the technology as a first‑line diagnostic tool, feeding back into procurement cycles across all regions.
Key Highlights:
Beyond the broader regional trends, specific countries are becoming focal points for investment. The United States remains a primary hub due to its strong venture‑capital ecosystem that backs startups developing ultra‑high‑frequency transducers and AI analytics. China’s rapid scale‑up of domestic manufacturers, combined with government subsidies for indigenous medical device production, positions it as a manufacturing powerhouse and a fast‑growing end‑user market. Germany leads Europe in precision engineering, attracting joint‑venture investments that combine German optics with Asian sensor technology. India’s burgeoning private‑hospital network, supported by foreign direct investment in health‑care infrastructure, makes it a lucrative market for both portable and on‑platform elastography solutions. Saudi Arabia and the United Arab Emirates are channeling sovereign‑wealth funds into smart‑hospital projects that mandate advanced imaging suites, including elastography, to meet Vision 2030 health objectives.
Modernisation of hospital infrastructure is a decisive catalyst for Sono‑elastography expansion. In North America, legacy imaging fleets are being replaced with integrated ultrasound platforms that include shear‑wave modules, aligning with hospital‑wide digital transformation roadmaps. European health‑systems are upgrading to value‑based care models; elastography’s ability to reduce unnecessary biopsies aligns with cost‑containment goals, prompting capital‑budget allocations for new units in France, the United Kingdom, and the Nordic countries. Asia‑Pacific’s massive hospital‑construction programmes—such as China’s “Healthy China 2030” initiative and India’s “Ayushman Bharat” expansion—explicitly list advanced ultrasound capabilities as required specifications. South America, particularly Brazil, is modernising its public‑hospital network with a focus on non‑invasive diagnostics to improve outcomes in underserved regions. In the Middle East & Africa, mega‑project hospitals in Saudi Arabia and the UAE are being built to International Society of Ultrasound in Medicine (ISUUM) standards, featuring on‑platform elastography as a baseline offering.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International Limited, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp, SuperSonic Imagine.
-> Key growth drivers include rising prevalence of chronic liver disease and cancer, increasing adoption of non‑invasive diagnostic tools, expanding point‑of‑care imaging in emerging markets, and advances in shear‑wave technology that improve diagnostic confidence.
-> North America holds the largest share due to early technology adoption and strong reimbursement frameworks, while Asia‑Pacific is the fastest‑growing region driven by rapid hospital infrastructure expansion in China, India, and Japan.
-> Emerging trends include integration of AI‑based image analysis for quantitative elastography, development of portable handheld elastography devices, and the use of elastography in cardiovascular and musculoskeletal applications beyond traditional liver imaging.
